Swedish Orphan Biovitrum AB News

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

01.06.21	Sobi at EHA virtual congress 2021: focus on results in PNH and treatment for ITP (PR Newswire)
01.06.21	Sobi at EHA virtual congress 2021: focus on results in PNH and treatment for ITP (PR Newswire)
25.05.21	Positive top-line results from the phase 3 PRINCE study of pegcetacoplan in treatment-naïve patients with PNH (PR Newswire)
25.05.21	Positive top-line results from the phase 3 PRINCE study of pegcetacoplan in treatment-naïve patients with PNH (PR Newswire)
20.05.21	Early use of anakinra reduces risk of mortality for patients with COVID-19 pneumonia, reduces ICU admission and increases likelihood of full recovery (PR Newswire)
26.04.21	Invitation - Presentation of Sobi's Q1 2021 results (PR Newswire)
26.04.21	Invitation - Presentation of Sobi's Q1 2021 results (PR Newswire)
26.03.21	Evaluation of haemophilia A treatment options shows favourable efficacy results for Elocta® (PR Newswire)
12.03.21	First patient dosed in phase 3 study with avatrombopag for treatment of ITP in children (PR Newswire)
12.03.21	First patient dosed in phase 3 study with avatrombopag for treatment of ITP in children (PR Newswire)
26.02.21	Rare Disease Day 2021: Pandemic illuminates every day social obstacles of living with a rare condition (PR Newswire)
26.02.21	Rare Disease Day 2021: Pandemic illuminates every day social obstacles of living with a rare condition (PR Newswire)
18.02.21	Sobi publishes report for the fourth quarter and full-year 2020 (PR Newswire)
18.02.21	Sobi publishes report for the fourth quarter and full-year 2020 (PR Newswire)
16.02.21	Kineret® (anakinra) approved in Russia for the treatment of CAPS (PR Newswire)
16.02.21	Kineret® (anakinra) approved in Russia for the treatment of CAPS (PR Newswire)
03.02.21	Invitation - Presentation of Sobi's Q4 and FY 2020 results (PR Newswire)
03.02.21	Invitation - Presentation of Sobi's Q4 and FY 2020 results (PR Newswire)
20.01.21	Doptelet® (avatrombopag) approved in the EU for treatment of ITP (PR Newswire)
20.01.21	Doptelet® (avatrombopag) approved in the EU for treatment of ITP (PR Newswire)
21.12.20	Sobi appoints new Head of North America ahead of launch phase (PR Newswire)
10.12.20	Sobi and Apellis report positive top-line results at 48 weeks from the phase 3 PEGASUS study of pegcetacoplan in PNH (PR Newswire)
10.12.20	Emapalumab submission in China for primary HLH (PR Newswire)
10.12.20	Realising opportunities for future growth and financial update: Sobi Capital Markets Day 2020 (PR Newswire)
07.12.20	Agenda: Sobi Capital Markets Day 2020 (PR Newswire)
19.11.20	Sobi and Apellis announce first patient dosed in potentially registrational ALS study of pegcetacoplan (PR Newswire)
06.11.20	Strong Sobi presence at American Society of Hematology 2020 Annual Meeting (PR Newswire)
04.11.20	Sobi launch Doptelet® (avatrombopag) in Europe (PR Newswire)
23.10.20	Invitation to the Sobi Capital Markets Day 2020 (PR Newswire)
22.10.20	Sobi publishes report for the third quarter 2020 (PR Newswire)
09.10.20	Sobi announces topline phase 3 data of avatrombopag for the treatment of Chemotherapy-Induced Thrombocytopenia (PR Newswire)
07.10.20	Invitation - Presentation of Sobi's Q3 2020 results (PR Newswire)
23.09.20	First patient randomised in the phase 3 DISSOLVE clinical programme of SEL-212 for Chronic Refractory Gout (PR Newswire)
18.09.20	Orfadin® (nitisinone) receives positive opinion from CHMP for treatment of AKU (PR Newswire)
10.09.20	New England Journal of Medicine publishes positive final results from phase 1/2a study of BIVV001 in people with severe haemophilia A (PR Newswire)
18.08.20	Sobi appoints Dr Ravi Rao as new Head of Research & Development (PR Newswire)
13.07.20	Data Presented at ISTH2020 Strengthens Evidence for Both Elocta® and Alprolix® in Previously Untreated Patients With Haemophilia (PR Newswire)
08.07.20	Data to be Presented at ISTH Virtual Congress Highlights Sobi's Commitment to Advancing Rare Haematology Treatments (PR Newswire)
06.07.20	Invitation - Presentation of Sobi's Q2 2020 Results (PR Newswire)
26.06.20	Successful Elocta Bid Means Increased Access for People With Haemophilia A in the UK (PR Newswire)
14.06.20	Sobi and Sanofi Donate up to 500 Million Additional IUs of Clotting Factor to WFH Humanitarian Aid Program (PR Newswire)
12.06.20	Sobi and Selecta Announce Strategic Licensing Agreement for SEL-212, a Phase 3-ready Novel Treatment for Chronic Refractory Gout (PR Newswire)
07.05.20	Results From Pivotal Phase 2/3 Study of Emapalumab in Patients With Primary HLH Published in New England Journal of Medicine (PR Newswire)
22.04.20	Invitation - Presentation of Sobi's Q1 2020 Results (PR Newswire)
22.04.20	Sobi™ Affiliate Florio GmbH, Launches a New Digital Platform Aiming to Improve the Lives of People with Haemophilia (PR Newswire)
20.04.20	Sobi Offers Advance Voting at the 2020 Annual General Meeting (PR Newswire)
17.04.20	New Data Shows Varied State of Haemophilia Treatment Around the World: Sobi (PR Newswire)
13.04.20	Sobi Sees Strong Revenue and EBITA Growth in the First Quarter 2020 (PR Newswire)
07.04.20	Sobi™ Publishes 2019 Annual and Sustainability Report (PR Newswire)
28.02.20	New Research Uncovers the Toll Rare Diseases Take on Relationships (PR Newswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Part Grp Hldg	1’246.50	1.51 %	K V
Geberit	522.80	1.20 %	K V
Roche Hldg G	253.70	1.04 %	K V
Sika	231.10	0.92 %	K V
Sonova Hldg	306.70	0.89 %	K V
Logitech Intl	70.44	0.26 %	K V
Kuehne+Nagel Int	208.50	0.24 %	K V
Zurich Insur Gr	548.20	0.11 %	K V
Swiss Life Hldg	727.20	0.00 %	K V
Nestle	75.92	-0.05 %	K V

Nachrichten zu Swedish Orphan Biovitrum AB

Aktien Top/Flop

Meistgelesene Nachrichten